Clinical Trial Update: PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update comparing PCD versus RCD regimens for Waldenström's macroglobulinemia in Phase 1/2; current status is not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Treatment | Phase 1, Phase 2 | Status: UNKNOWN